Tranexamic Acid Should NOT Be Used in Variceal Bleeding
Tranexamic acid is contraindicated in acute variceal bleeding and should not be administered to these patients. This is a strong recommendation based on high-quality guideline evidence and a large randomized controlled trial 1.
The Evidence Against Tranexamic Acid
The 2022 EASL (European Association for the Study of the Liver) Clinical Practice Guidelines explicitly state with a Level of Evidence 2, strong recommendation that tranexamic acid should not be used in patients with cirrhosis and active variceal bleeding 1.
This recommendation is based on the HALT-IT trial, a large international randomized placebo-controlled study of 12,009 patients with acute upper gastrointestinal bleeding, where nearly 50% had suspected variceal bleeding 1, 2. The trial found:
- No mortality benefit: Death due to bleeding within 5 days occurred in 4% of both tranexamic acid and placebo groups (RR 0.99,95% CI 0.82-1.18) 2
- No reduction in bleeding: Tranexamic acid did not reduce bleeding events 2
- Increased thrombotic risk: An almost 2-fold increase in venous thromboembolic events was observed in the tranexamic acid group, with this risk concentrated specifically in patients with liver disease/suspected variceal bleeding 1
Why Tranexamic Acid Fails in Variceal Bleeding
The mechanism of variceal bleeding differs fundamentally from other bleeding scenarios. Variceal hemorrhage is primarily a mechanical problem driven by portal hypertension, not a hemostatic defect 1. Additionally:
- Critically ill patients with cirrhosis frequently exist in a hypofibrinolytic state, making antifibrinolytic therapy ineffective 1
- Hemostasis plays a limited role in controlling variceal bleeding compared to portal pressure reduction 1
What TO Use Instead
Standard therapy for variceal bleeding includes 1:
- Vasoactive therapy (terlipressin, somatostatin, or octreotide) - initiated before endoscopy
- Antibiotics - started immediately
- Endoscopic band ligation (EBL) - performed urgently
This combination addresses the underlying portal hypertension and achieves hemostasis through mechanical and pharmacological portal pressure reduction, not through correction of coagulation.
Critical Caveat: Recent Contradictory Data
A 2024 randomized controlled trial of 600 patients with Child-Pugh B or C cirrhosis showed tranexamic acid reduced 5-day treatment failure (6.3% vs 13.3%, p=0.006), particularly by preventing bleeding from post-EVL sites 3. However, this study did not show mortality benefit, and the EASL guidelines (which incorporate the larger HALT-IT trial data) take precedence given the demonstrated thrombotic risk.
The Thrombotic Risk Is Real
The FDA label for tranexamic acid warns of thromboembolic events including deep vein thrombosis, pulmonary embolism, and cerebral thrombosis 4. In the cirrhosis population specifically, this risk is amplified due to the paradoxical prothrombotic state that can exist in acute-on-chronic liver failure 1.
Bottom Line for Clinical Practice
Do not administer tranexamic acid for variceal bleeding. Focus on the proven triad of vasoactive drugs, antibiotics, and endoscopic therapy. The lack of mortality benefit combined with increased thrombotic complications makes tranexamic acid harmful rather than helpful in this specific population, despite its effectiveness in other bleeding scenarios 1, 5, 2.